Metropolis Healthcare Limited, one of the leading and most well-known Indian diagnostics organizations with its headquarters in Mumbai, has announced the record date for its corporate action in the ...

Based on the one-year price targets offered by 18 analysts, the average target price for Metropolis Healthcare Ltd (BOM:542650) is $2,234.33 with a high estimate of $2,600 and a low estimate of $1,655 ...

Based on the one-year price targets offered by 17 analysts, the average target price for Metropolis Healthcare Ltd (BOM:542650) is $2,157.18 with a high estimate of $2,537 and a low estimate of $1,655 ...

Based on the one-year price targets offered by 16 analysts, the average target price for Metropolis Healthcare Ltd (BOM:542650) is $2,167.88 with a high estimate of $2,650.00 and a low estimate of ...

Metropolis Healthcare will trade ex-date on March 20 for a Bonus issue in the ratio of 3:1.

Under India's T+1 settlement cycle, investors must buy the shares at least one trading day before the record date to be eligible.

The Carlyle Group said Wednesday that it has bought a stake in Metropolis Healthcare Ltd. Dr. GSK Velu and his affiliates are the sellers. Financial terms were not announced. Metropolis Healthcare is ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Metropolis Healthcare share price surged over 5 percent in Wednesday's trading session after the strong December quarter earnings. The company reported a 15.4 percent rise in its net profit to Rs 31.4 ...

Metropolis Healthcare Ltd, India’s second-largest pathology chain, said Monday it will acquire oncology-focused diagnostic services provider Core Diagnostics Pvt Ltd for Rs 246.83 crore ($29 million).

Metropolis Healthcare Limited on Monday announced that its Board of Directors has approved the acquisition of Delhi-NCR headquartered Core Diagnostics. According to the company’s statement, this ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...